Investment case
Cytokinetics, Incorporated
CYTK · 3 developments mapped · last assessed 2026-08-30
Market Ontology has mapped 3 macro, policy, and market developments to Cytokinetics, Incorporated since 2026-08-30. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for CYTK yet, so no modelled value is shown. The CYTK valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run CYTK on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Strongest support
Cytokinetics Presents Positive Aficamten Phase Data at ESC Congress 2026
Direct positive clinical trial results for a key pipeline asset, increasing probability of regulatory approval and commercial success.
· Moves probability of success (pos) for aficamten, peak sales estimates for aficamten, discount rate (wacc) due to reduced risk
What changed, by assumption
- 2026-08-30Cytokinetics Presents Positive Aficamten Phase Data at ESC Congress 2026
- 2026-08-30Cytokinetics Presents Positive Aficamten Phase 3 Data at ESC Congress 2026
- 2026-08-30Cytokinetics Presents Aficamten Phase 3 Data at ESC Congress 2026
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-08-30 | Cytokinetics Presents Positive Aficamten Phase Data at ESC Congress 2026 | Bullish | 1-3m | 0.90 |
| 2026-08-30 | Cytokinetics Presents Aficamten Phase 3 Data at ESC Congress 2026 | Bullish | 1-3m | 0.90 |
| 2026-08-30 | Cytokinetics Presents Positive Aficamten Phase 3 Data at ESC Congress 2026 | Bullish | 1-3m | 0.90 |